Company news
Spectracure Ab (OMXSTO:SPEC) news
Spectracure Ab news releases on 6ix. Latest, Jun 1, 2026: Spectracure Appoints Fata Mrsic As CFO
Press releases & updates
Spectracure Appoints Fata Mrsic As CFO
June 1, 2026
Spectracure Q1 Net Loss After Tax SEK 6.1 Mln
May 27, 2026
SPEC: Promising clinical progress, but widened losses and liquidity risks raise going concern doubts
February 27, 2026
Spectracure Signs Agreement With Rostock Hospital For Prostate Cancer Study
January 26, 2026
Spectracure To Get SEK 31.3 Mln If All TO5 Warrants Utilized
January 15, 2026
Spectracure Q3 Net Loss SEK 35 Mln
November 13, 2025
Spectracure Says Study Shows Significant PSA Reduction In Prostate Cancer Patients
November 4, 2025
Spectracure Signs Agreement With Cheplapharm For Verteporfin Supply
October 21, 2025
Spectracure Q-Pro Patent Approved In Japan
October 13, 2025
Spectracure Gets Approval To Commence Clinical Trial
October 8, 2025
Spectracure Appoints Johannes Swartling As CEO
October 1, 2025
Spectracure Reports Positive Results In Prostate Cancer Study
September 22, 2025
SPEC: Clinical progress and new funding strengthen position despite ongoing losses
August 15, 2025
SPEC: Q1 2025 saw continued losses and a planned rights issue as SpectraCure advances clinical studies
May 28, 2025
SPEC: Net loss widened as SpectraCure advanced clinical trials, with new funding needed by mid-2025
February 20, 2025
SPEC: Losses widened in Q3 as SpectraCure advances clinical studies and seeks new funding
November 14, 2024
SPEC: Net loss widened in H1 2024 as SpectraCure advanced Q-PRO® clinical studies and market plans
August 15, 2024
SpectraCure takes the next step in the work with the new clinical study
February 23, 2024
SpectraCure has decided to seek approval for a clinical study of primary prostate cancer
November 16, 2023
SpectraCure has been awarded an additional EU grant for industrialisation of the company's treatment system Q-PRO®
June 27, 2023
SpectraCures signs Letter of Intent with Cheplapharm
December 7, 2022
SpectraCure has been approved a grant from EU of € 125,000
June 7, 2022
SpectraCure : Status update regarding clinical studies for the treatment of patients with recurrent prostate cancer
March 5, 2021
SpectraCure publ : raises approximately SEK 140 million through a fully subscribed rights issue
June 26, 2020